Susquehanna Fundamental Investments LLC Invests $1.80 Million in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Susquehanna Fundamental Investments LLC bought a new stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 182,925 shares of the company's stock, valued at approximately $1,796,000. Susquehanna Fundamental Investments LLC owned approximately 0.32% of Ginkgo Bioworks at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in DNA. SBI Securities Co. Ltd. bought a new position in shares of Ginkgo Bioworks in the fourth quarter valued at approximately $29,000. KBC Group NV bought a new stake in shares of Ginkgo Bioworks in the 4th quarter worth $31,000. Price T Rowe Associates Inc. MD raised its holdings in shares of Ginkgo Bioworks by 4.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 82,815 shares of the company's stock valued at $814,000 after purchasing an additional 3,152 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in Ginkgo Bioworks in the 4th quarter worth about $46,000. Finally, Bank of New York Mellon Corp increased its stake in Ginkgo Bioworks by 48.2% in the 4th quarter. Bank of New York Mellon Corp now owns 23,061 shares of the company's stock valued at $226,000 after buying an additional 7,503 shares during the last quarter. 78.63% of the stock is owned by institutional investors and hedge funds.

Ginkgo Bioworks Price Performance

Shares of Ginkgo Bioworks stock traded down $0.30 on Tuesday, reaching $6.62. 357,430 shares of the company traded hands, compared to its average volume of 1,471,470. Ginkgo Bioworks Holdings, Inc. has a 52 week low of $5.00 and a 52 week high of $41.20. The company has a 50 day moving average of $7.20 and a 200 day moving average of $9.12. The firm has a market capitalization of $384.19 million, a PE ratio of -0.50 and a beta of 1.29.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.